parallel randomized trial

S003154

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Other conditionsS003154

Design

Randomized: 37
Start year: 2012
Treatment: 0.57 weeks, follow-up 0.57 weeks
Countries: Netherlands (1 sites)
Sponsor: (industry)
Eligibility: adults 18 to 75 without diabetes, elective hip surgery with dabigatran

Conduct and analysis

Blinding: double blind
Sequence generation: other adequate
Allocation concealment: pharmacy or sealed
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: modified itt
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Liraglutide 1.2 mg subcutaneous once daily Liraglutide	general anesthesia, antiemetic prophylaxis, dabigatran; lifestyle: not reported		19
A2	Placebo Placebo	general anesthesia, antiemetic prophylaxis, dabigatran; lifestyle: not reported		17

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Liraglutide 1.2 mg subcutaneous once daily A1	Placebo A2
age	mean (years)	57	59
age	sd (years)	12	11
bmi	mean (kg/m2)	28	27
bmi	sd (kg/m2)	5	5
female	n	9	13
female	percent	47	77
hba1c	mean (mmol/mol)	38	36
hba1c	sd (mmol/mol)	3	3
other ethnicity surinam antillean	n	2
other ethnicity surinam antillean	percent	11
other race other	n	1
other race other	percent	5
white	n	16	17
white	percent	84	100

Results

5 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Discontinuation due to adverse events (1 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 19	not stated; other; R0022305:Results

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				9 / 19	not stated; other; R0022305:Table 2
	A2	events				5 / 17	not stated; other; R0022305:Table 2

Vomiting (1 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				3 / 19	not stated; other; R0022305:Table 2

Discontinuation due to gastrointestinal adverse events (1 lines; O27E)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 19	not stated; other; nausea; R0022305:Results